C12N 2760/16311
Influenzavirus c, i.e. influenza c virus
Official title: Influenzavirus C, i.e. influenza C virus
C12N2760/16311 (Influenzavirus c, i.e. influenza c virus) appears on 47 US grants and 88 published applications in this corpus.
Search patents in C12N- Granted patents
- 47
- Published applications
- 88
- Assignees
- 50
- Inventors
- 143
- Latest grant
- 10 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 0 | 4 |
| 2008 | 0 | 3 |
| 2009 | 2 | 2 |
| 2010 | 2 | 4 |
| 2011 | 0 | 3 |
| 2012 | 3 | 3 |
| 2013 | 3 | 8 |
| 2014 | 3 | 5 |
| 2015 | 5 | 6 |
| 2016 | 5 | 7 |
| 2017 | 0 | 3 |
| 2018 | 5 | 6 |
| 2019 | 0 | 7 |
| 2020 | 3 | 3 |
| 2021 | 6 | 2 |
| 2022 | 2 | 8 |
| 2023 | 1 | 4 |
| 2024 | 2 | 4 |
| 2025 | 3 | 1 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/16334Use of virus or viral component as vaccineIndexing code30
- C12N 2760/16322New viral proteins or individual genes, new structural or functional aspects ofIndexing code16
- C12N 2760/16351Methods of production or purification of viral materialIndexing code6
- C12N 2760/16323Virus like particles [vlp]Indexing code3
- C12N 2760/16321Viruses as suchIndexing code2
- C12N 2760/16361Methods of inactivation or attenuationIndexing code2
- C12N 2760/16332Use of virus as therapeutic agent, other than vaccineIndexing code1
- C12N 2760/16333Use of viral protein as therapeutic agent other than vaccineIndexing code1
Recent patents
- Optimized anti-CD3 arm in the generation of t-cell bispecific antibodies for immunotherapy10 Feb 2026US 12,545,730 B2Shandong Boan Biotechnology Co., Ltd.
- Nanoparticle-based influenza virus vaccines and uses thereof7 Oct 2025US 12,433,943 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Human antibodies to Fel d1 and methods of use thereof18 Mar 2025US 12,252,530 B2Regeneron Pharmaceuticals, Inc.
- Influenza vaccines25 Feb 2025US 12,234,263 B2InvVax, Inc.
- Stabilized hemagglutinin (HA) trimers as influenza vaccine antigens8 Oct 2024US 12,109,261 B1The Scripps Research Institute
- Vaccination using high-density microprojection array patch17 Sep 2026US 2026/0273256 A1Vaxxas Pty Limited
- Production of viruses in cell culture9 Jan 2025US 2025/0011731 A1Commonwealth Scientific and Industrial Research Organisation
- Multivalent influenza vaccines15 Aug 2024US 2024/0269258 A1Sanofi Pasteur Limited
- Cryptic proteins expressed from defective viral genomes interfere with influenza virus replication11 Jul 2024US 2024/0228980 A1Wisconsin Alumni Research Foundation
- Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses9 May 2024US 2024/0150409 A1ISD Immunotech ApS
Most cited
By later US patents
- Viruses encoding mutant membrane protein33US 7,588,769 B2Wisconsin Alumni Research Foundation · 2009
- Human antibodies to Fel d1 and methods of use thereof31US 9,079,948 B2Regeneron Pharmaceuticals, Inc. · 2015
- Yeast-based vaccine for inducing an immune response25US 7,736,642 B2GlobeImmune, Inc. · 2010
- Immunological preparations20US 4,117,113 ANational Research Development Corporation · 1978
- Compositions that include hemagglutinin14US 8,420,102 B2VaxInnate Corporation · 2013